Fibrinogen mediated activation of platelet aggregation and thromboxane A2 release: pathological implications in vascular disease.

Content Provider	Semantic Scholar
Author	Mikhailidis, Dimitri P. Barradas, María Del Rocío Aguilar Maris, Assimo Jeremy, Jamie Yancey Dandona, Paresh
Copyright Year	1985
Abstract	The effect of a human fibrinogen preparation on in vitro platelet aggregation was assessed. Platelets were obtained from healthy volunteers. Human fibrinogen induced platelet aggregation in 65% of platelet rich plasma samples and enhanced submaximal platelet aggregation induced by heparin or by several conventional agonists in all samples. Aggregation induced by fibrinogen alone was reversed by the in vitro addition of human albumin. Fibrinogen induced aggregation was associated with the release of the vasoconstrictor, thromboxane A2. Preincubation with indomethacin inhibited both the aggregation and the release of thromboxane A2. Fibrinogen had no effect on in vitro vascular prostaglandin I2 synthesis (rat aortic rings) during a 60 minute incubation. The observed effects of fibrinogen on platelet function may be relevant to clinical conditions in which hyperaggregability of platelets is associated with hyperfibrinogenemia and thrombosis.
Starting Page	1569
Ending Page	1575
Page Count	7
File Format	PDF HTM / HTML
Alternate Webpage(s)	http://jcp.bmj.com/content/jclinpath/38/10/1166.full.pdf
PubMed reference number	3902901v1
Volume Number	38
Issue Number	10
Journal	Journal of clinical pathology
Language	English
Access Restriction	Open
Subject Keyword	Blood Platelets Epoprostenol Hyperfibrinogenemia In Vitro [Publication Type] Indomethacin Platelet Count measurement Platelet aggregation Platelet rich plasma Prostaglandins Thrombosis Thromboxane A2 Thromboxanes Vascular Diseases Vasoconstrictor Agents fibrinogen complex location heparin
Content Type	Text
Resource Type	Article